{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(1)"],"submitter":["Foster L"],"pubmed_abstract":["In the primary analysis (32.3-month median follow-up) of the randomized, phase 3 AURIGA study (NCT03901963), daratumumab-lenalidomide (D-R) maintenance significantly improved MRD-negative conversion rates and reduced the risk of disease progression or death by 47% versus R maintenance in anti-CD38 monoclonal antibody-naïve and post-transplant MRD-positive patients with newly diagnosed MM. Here, we present a post hoc analysis across relevant subgroups, including high-risk cytogenetic abnormalities (HRCAs) per original, revised, and modified International Myeloma Society (IMS) 2024 criteria. MRD-negative (10<sup>-5</sup>) conversion rates by 12 months of maintenance were higher for D-R versus R across cytogenetically high-risk subgroups per original (31.8% vs 6.7%), revised (43.8% vs 13.3%),"],"journal":["Blood cancer journal"],"pagination":["154"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12500855"],"repository":["biostudies-literature"],"pubmed_title":["Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses."],"pmcid":["PMC12500855"],"pubmed_authors":["Voorhees P","Chaulagain CP","Krevvata M","Silbermann R","Lin TS","Shain KH","Costello C","Pei H","Sborov DW","Carson R","Cowan AJ","Anderson LD","Larson S","Cortoos A","Foster L","Chung A","Patel S","Khare V","Badros A","Pettijohn E"],"additional_accession":[]},"is_claimable":false,"name":"Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.","description":"In the primary analysis (32.3-month median follow-up) of the randomized, phase 3 AURIGA study (NCT03901963), daratumumab-lenalidomide (D-R) maintenance significantly improved MRD-negative conversion rates and reduced the risk of disease progression or death by 47% versus R maintenance in anti-CD38 monoclonal antibody-naïve and post-transplant MRD-positive patients with newly diagnosed MM. Here, we present a post hoc analysis across relevant subgroups, including high-risk cytogenetic abnormalities (HRCAs) per original, revised, and modified International Myeloma Society (IMS) 2024 criteria. MRD-negative (10<sup>-5</sup>) conversion rates by 12 months of maintenance were higher for D-R versus R across cytogenetically high-risk subgroups per original (31.8% vs 6.7%), revised (43.8% vs 13.3%),","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T06:18:55.784Z","creation":"2026-05-06T03:12:42.503Z"},"accession":"S-EPMC12500855","cross_references":{"pubmed":["41053004"],"doi":["10.1038/s41408-025-01355-0"]}}